Non-Small Cell Lung Cancer Market will project a CAGR of 13.9% during the forecast up to 2030.
Ø According to data published by the Institute for Clinical and Economic Review (ICER) and the National Institutes of Health (NIH), approximately 85% of lung cancer cases in the United States are NSCLC. Squamous cell carcinoma accounted for 30% of the cases, adenocarcinoma accounted for 40%, and large-cell carcinoma accounted for 15%. Furthermore, all other country-based registries reported nearly the same percentage of NSCLC and its major subtypes.
Ø Data Bridge Market Research analyses that the non-small cell lung cancer market which is USD 26948.36 million in 2022, is expected to reach USD 76334.72 million by 2030, at a CAGR of 13.9% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Ø Non-small cell lung carcinoma (NSCLC), also known as non-small cell lung cancer, is the most common type of lung cancer. The term "non-small cell" refers to the appearance of cancer cells under a microscope. Small cell lung cancer is named after the size of the cells (SCLC). According to the American Cancer Society, about 80 to 85 percentTrusted Source of all lung carcinomas fall into the non-small cell category. NSCLC is less likely to spread than SCLC and has a higher survival rate. The majority of people with early-stage NSCLC survive at least 5 years, but the survival rate is much lower if the cancer has spread to other tissues at the time of diagnosis.
Ø The large scale Non-Small Cell Lung Cancer Market report is a perfect source to acquire thorough synopsis on the market study, analysis, estimation and the factors influencing the Non-Small Cell Lung Cancer Market industry. The report also presents with the statistics on the existing state of the industry. And thus proves to be an important source of guidance and direction for companies and investors that are interested in this market. It becomes easy to achieve supreme level of market insights and obtain knowhow of the best market opportunities into the specific markets with this market report. Moreover, Non-Small Cell Lung Cancer Market report also explains a widespread evaluation of the market’s growth prospects and restrictions.
Ø Global Non-Small Cell Lung Cancer Market report has been prepared by keeping in mind the customer requirements which assist them in increasing their return on investment (ROI). Furthermore, it endows with historic data, present market trends, environment, technological innovation, upcoming technologies and the technical progress in the related industry. This market research report encompasses a far-reaching research on the current conditions of the Non-Small Cell Lung Cancer Market industry, potential of the market in the present and the future prospects. The persuasive Non-Small Cell Lung Cancer Market report also covers very important aspect which is competitive intelligence and with this businesses can gain competitive advantage to thrive in the market.
Ø Access Full Report: https://www.databridgemarketresearch.com/reports/global-non-small-cell-lung-cancer-market
Non-Small Cell Lung Cancer Market Segmentation
The non-small cell lung cancer market is segmented on the basis of cancer type, molecule type, drug class, treatment type, therapy type, end user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Cancer Type
· Non-Small Cell Lung Cancer
· Metastatic Lung Cancer
· Pulmonary Neuroendocrine Tumours
· Mediastina Tumours
· Mesothelioma
· Chest Wall Tumours
Type
· Adenocarcinomas
· Squamous Cell Carcinoma
· Large Cell Carcinomas
· Others
Molecule Type
· Small Molecules
· Biologics
Drug Class
· Alkylating Agents
· Antimetabolites
· EGFR Inhibitors
· Mitotic Inhibitors
· Multi-kinase Inhibitors
· Others
Treatment Type
· Chemotherapy
· Radiation Therapy
· Targeted Therapy
· Immunotherapy
· Others
Diagnosis
· CT Scan
· X-Rays
· Sputum Cytology
· Bronchoscopy
· Laboratory Tests
· Thoracoscopy
· Others
Therapy Type
· Single Drug Therapy
· Combination Therapy
End User
· Hospitals
· Homecare
· Specialty Clinics
· Others
Distribution Channel
· Hospital Pharmacy
· Retail Pharmacy
· Online
· Others
Ø Request Access for Sample Report: https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-non-small-cell-lung-cancer-market
The major players covered in the Non-Small Cell Lung Cancer Market
Ø F. Hoffmann-La Roche Ltd. (Switzerland)
Ø Mylan N.V. (U.S.)
Ø Teva Pharmaceutical Industries Ltd. (Israel)
Ø Sanofi (France)
Ø Pfizer Inc. (U.S.)
Ø GSK plc (U.K.)
Ø Novartis AG (Switzerland)
Ø Bayer AG (Germany)
Ø Lilly (U.S.)
Ø Merck & Co., Inc. (U.S.)
Ø Sun Pharmaceutical Industries Ltd. (India)
Ø Aurobindo Pharma (India)
Ø Lupin (India)
Ø CLOVIS ONCOLOGY (U.S.)
Ø Johnson & Johnson Private Limited (U.S.)
TOC of the report
Chapter One: Introduction
Chapter Two: Market Segmentation
Chapter Three: Market Overview
Chapter Four: Executive Summary
Chapter Five: Premium Insights
Get TOC details from here: https://www.databridgemarketresearch.com/toc/?dbmr=global-non-small-cell-lung-cancer-market
